Power Law company profile

Shanghai Henlius Biotech

Biotech & Life Sciences · Huangpu, China · Founded 2009 · IPO 2019 Unicorn

Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services

Valuation

$5.33B

Market cap · May/2026

Revenue

$917M

Latest reported FY

EBITDA

$254M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

6 investors on Shanghai Henlius Biotech's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 6 investors entered at this stage

CICC

ShenZhen GTJA Investment Group

Korea Investment Partners

Loyal Valley Capital

The Cathay Funds

Founder H Fund

Global footprint

Where Shanghai Henlius Biotech has talent and traffic

Workforce by country

9 countries with
team presence

🇨🇳 China88.8%

🇺🇸 United States3.1%

🇦🇺 Australia1.7%

🇭🇰 Hong Kong1.6%

🇸🇬 Singapore1.3%

Top 5 of 9 shown

Web traffic by country

44K monthly visits
across markets

🇩🇰 Denmark52%

🇯🇵 Japan12.5%

🇺🇸 United States6.8%

🏳️ Korea6.6%

🏳️ Republic of3.9%

Top 5 markets shown

Patent intelligence

$49M patent portfolio · 148 active families

Estimated portfolio value

$49M

0.91% of market cap · 6.7× smaller than top peer Genmab ($328M)

148 active patent families

Where Shanghai Henlius Biotech innovates Antiendomysial antibodiesMolecular biologyBiochemistryImmunologyAnti antibody

Where Shanghai Henlius Biotech concentrates vs peers

Each axis is a top-10 topic across Shanghai Henlius Biotech and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Shanghai Henlius Biotech

An AI-synthesized read of the highest-engagement posts about Shanghai Henlius Biotech on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Henlius Biotech on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles